Drug pricing negotiations between the UK government and pharmaceutical companies hit a roadblock recently, leading to a collapse in talks. The impasse arose as industry leaders expressed concerns over the UK’s pricing system, labeling it as ‘uncompetitive’ and potentially detrimental to future investments in the sector. While Health Secretary Wes Streeting lauded the government’s offer as unprecedented, drugmakers pushed back, seeking direct engagement with Prime Minister Keir Starmer to address their grievances.
The Labour government in the UK aims to foster investment to enhance productivity, but this objective faces challenges due to constraints in public finances and commitments to revamp the National Health Service (NHS). The deadlock in drug pricing discussions comes amidst global pressures, with reports suggesting that US President Donald Trump is advocating for aligning international drug prices more closely with the higher levels observed in the United States.
At the core of the dispute lies the UK’s voluntary scheme for branded medicines pricing, access, and growth (VPAG). In a proposal earlier this year, the UK government suggested a significant increase in the Statutory Scheme payment rate for newer branded medicines, from 15.5% to 32.2% of the companies’ NHS sales by the latter half of 2025. This move, however, faced resistance from pharmaceutical companies citing that the escalating mandatory payments were stifling growth, with the current rates ranging between 23.5% and 35.6% of sales revenue, significantly higher than those in other European nations.
One of the key grievances raised by the industry pertains to the system’s requirement for companies to rebate sales to the government once NHS spending on medicines surpasses a predefined threshold, currently set at approximately 23% of sales above the budget cap—significantly higher than the rates witnessed in most European countries. Despite government offers to reduce this rate to around 18-19%, industry representatives argue that the figure remains disproportionately high compared to global standards, advocating for a single-digit level instead.
Concerns have also been voiced regarding the government’s plan to double medicine spending from 0.3% to 0.6% of GDP over the next decade, scheduled to take effect only in 2029. This delay in providing relief further compounds the challenges faced by pharmaceutical companies operating in the UK. Executives, such as Novartis AG’s Johan Kahlström, have highlighted the country’s diminishing competitiveness, prompting firms to prioritize investments in markets like the US, China, and Japan, where innovation is more robustly rewarded.
Despite the government’s assertions that its proposals entail a substantial reduction in rebate levels and increased investment in medicines, the industry remains skeptical. The repercussions of the standoff are already being felt, with reports indicating that AstraZeneca Plc CEO Pascal Soriot has deferred plans for a vaccine facility in Britain, underscoring the tangible impacts of the pricing dispute on strategic decisions within the pharmaceutical sector.
- The UK drug pricing impasse highlights fundamental disagreements between pharmaceutical companies and the government, centered on rebates and mandatory payments.
- Industry leaders express concerns over the UK’s pricing system being ‘uncompetitive’, potentially deterring future investments in the sector.
- Global pressures, including calls from the US to align international drug prices with higher US levels, add complexity to the pricing negotiations.
- Delays in implementing proposed changes, such as doubling medicine spending to 0.6% of GDP by 2029, exacerbate challenges for pharmaceutical firms operating in the UK.
Read more on benzinga.com